Financials data is unavailable for this security.
View more
Year on year JiangXi Tianxin Pharmaceutical Co Ltd 's revenues fell -18.34% from 2.30bn to 1.88bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 622.12m to 475.85m, a -23.51% decrease.
| Gross margin | 40.17% |
|---|---|
| Net profit margin | 26.86% |
| Operating margin | 31.88% |
| Return on assets | 9.91% |
|---|---|
| Return on equity | 11.68% |
| Return on investment | 10.68% |
More ▼
Cash flow in CNYView more
In 2023, JiangXi Tianxin Pharmaceutical Co Ltd increased its cash reserves by 11.51%, or 238.24m. The company earned 729.21m from its operations for a Cash Flow Margin of 38.75%. In addition the company used 303.15m on investing activities and also paid 215.59m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.93 |
|---|---|
| Tangible book value per share | 9.49 |
More ▼
Balance sheet in CNYView more
| Current ratio | 8.56 |
|---|---|
| Quick ratio | 7.14 |
| Total debt/total equity | 0.0337 |
|---|---|
| Total debt/total capital | 0.0326 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -29.58% and -23.51%, respectively.
| Div yield(5 year avg) | 0.90% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 44.44% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -10.85 |
More ▼
